| Literature DB >> 26484768 |
Valeria Velasco1, Esra Buyukcangaz2, Julie S Sherwood3, Ryan M Stepan3, Ryan J Koslofsky3, Catherine M Logue4.
Abstract
Different clones of methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus have been found in humans as well as in animals and retail meat. However, more information about the genetic characteristics and similarities between strains is needed. The aim of this study was to identify and characterize Staphylococcus aureus from humans, and to compare their characteristics with isolates of animal origin. A total of 550 nasal swabs were taken from healthy humans, and S. aureus was isolated and identified. Positive S. aureus isolates were subjected to molecular typing and susceptibility testing. In addition, 108 MRSA isolates recovered from clinical patients in the state of North Dakota and 133 S. aureus isolates from animals and meat previously analyzed were included. The nasal carriage of S. aureus in healthy people was 7.6% and, in general, clones were genetically diverse. None of the S. aureus strains obtained from healthy people were mecA- or PVL-positive. A total of 105 (97.2%) MRSA isolates from clinical cases harbored the mecA gene and 11 (10.2%) isolated from blood stream infections harbored the PVL gene. The most common resistance profile among S. aureus from healthy people was penicillin, and from clinical cases were erythromycin-penicillin-ciprofloxacin. The rate of multidrug resistance (MDR) was 70% in humans. Most of the S. aureus harboring mecA and PVL genes were identified as ST5 and ST8, and exhibited MDR. However, S. aureus isolates of animal origin used for comparison exhibited a lower rate of MDR. The most common resistance profiles in isolates of animal origin were penicillin-tetracycline and penicillin-tetracycline-erythromycin, in animals and raw meat, respectively. The ST5 was also found in animals and meat, with ST9 and ST398 being the major clones. The genetic similarity between clones from humans and meat suggests the risk of spread of S. aureus in the food chain.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26484768 PMCID: PMC4618867 DOI: 10.1371/journal.pone.0140497
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Source and characteristics of S. aureus isolates of animal origin used in the study.
| Source |
| 16S rRNA |
| PVL |
|---|---|---|---|---|
|
| ----------No.---------- | ------------------------No.------------------------ | ||
|
| 26 | 26 | 0 | 0 |
|
| 30 | 30 | 0 | 0 |
|
| 2 | 2 | 0 | 0 |
|
| 58 | 58 | 0 | 0 |
|
| ||||
|
| 35 | 35 | 5 | 0 |
|
| 25 | 25 | 0 | 0 |
|
| 9 | 9 | 0 | 0 |
|
| 69 | 69 | 5 | 0 |
|
| ||||
|
| 4 | 4 | 0 | 0 |
|
| 0 | 0 | 0 | 0 |
|
| 2 | 2 | 0 | 0 |
|
| 6 | 6 | 0 | 0 |
Adapted from Buyukcangaz et al. (2013) [15].
Antimicrobial resistance profiles of S. aureus isolates of animal origin used in this study.
| Antimicrobial resistance profile | Antimicrobial subclasses | Isolates | Source | Isolates |
|---|---|---|---|---|
| ----------No.---------- | --No.-- | -----------------No.----------------- | ||
|
| 7 | 1 | Pork meat | 1 |
|
| 6 | 1 | Pork meat | 1 |
|
| 4 | 2 | Pig | 2 |
|
| 4 | 1 | Pork meat | 1 |
|
| 3 | 14 | Pork meat | 11 |
| 3 | ||||
|
| 3 | 1 | Sheep | 1 |
|
| 3 | 1 | Pork meat | 1 |
|
| 3 | 1 | Pig | 1 |
|
| 2 | 4 | Pork meat | 3 |
| 1 | ||||
|
| 2 | 5 | Pork meat | 5 |
|
| 2 | 39 | Pig | 19 |
| Sheep | 17 | |||
| Pork meat | 2 | |||
| Chicken meat | 1 | |||
|
| 1 | 4 | Chicken meat | 3 |
| Chicken deli meat | 1 | |||
|
| 1 | 21 | Pig | 7 |
| Sheep | 1 | |||
| Pork meat | 4 | |||
| Beef | 4 | |||
| Chicken meat | 3 | |||
| Ham | 2 | |||
|
| 1 | 10 | Sheep | 6 |
| Pork meat | 3 | |||
| Chicken meat | 1 | |||
Ciprofloxacin (CIP); chloramphenicol (CHL); erythromycin (ERY); gentamicin (GEN); kanamycin (KAN); quinupristin/dalfopristin (QUI); penicillin (PEN); and tetracycline (TET).
a mecA positive.
Adapted from Buyukcangaz et al. (2013) [15], considering the resistance according to CLSI (2012) criteria [34].
Nucleotide sequence of the primers used for detection of 16S rRNA, mecA, Panton-Valentine leukocidin, mecA LGA251, arcC, aroE, glpF, gmk, pta, tpi, and yqiL genes.
| Primer | Oligonucleotide sequence | Amplicon Size (bp) |
|---|---|---|
|
| 5’-AACTCTGTTATTAGGGAAGAACA-3’ | 756 |
|
| 5’-CCACCTTCCTCCGGTTTGTCACC-3’ | |
|
| 5’-GTAGAAATGACTGAACGTCCGATAA-3’ | 310 |
|
| 5’-CCAATTCCACATTGTTTCGGTCTAA-3’ | |
|
| 5’-ATCATTAGGTAAAATGTCTGGACATGATCCA-3’ | 433 |
|
| 5’-GCATCAAGTGTATTGGATAGCAAAAGC-3’ | |
|
| 5'-TCACCAGGTTCAAC[Y]CAAAA-3' | 356 |
|
| 5'-CCTGAATC[W]GCTAATAATATTTC-3' | |
|
| 5'-GAAAAAAAGGCTTAGAACGCCTC-3' | 718 |
|
| 5'-CCTGAATC[W]GCTAATAATATTTC-3' | |
|
| 5'-GAAAAAAAGGCTTAGAACGAATC-3' | 138 |
|
| 5'-GATCTTTTCCGTTTTCAGC-3' | |
|
| 5'-TTGATTCACCAGCGCGTATTGTC-3' | 456 |
|
| 5'-AGGTATCTGCTTCAATCAGCG-3' | |
|
| 5'-ATCGGAAATCCTATTTCACATTC-3' | 456 |
|
| 5'-GGTGTTGTATTAATAACGATATC-3' | |
|
| 5'-CTAGGAACTGCAATCTTAATCC-3' | 465 |
|
| 5'-TGGTAAAATCGCATGTCCAATTC-3' | |
|
| 5'-ATCGTTTTATCGGGACCATC-3' | 429 |
|
| 5'-TCATTAACTACAACGTAATCGTA-3' | |
|
| 5'-GTTAAAATCGTATTACCTGAAGG-3' | 474 |
|
| 5'-GACCCTTTTGTTGAAAAGCTTAA-3' | |
|
| 5'-TCGTTCATTCTGAACGTCGTGAA3' | 402 |
|
| 5'-TTTGCACCTTCTAACAATTGTAC-3' | |
|
| 5'-CAGCATACAGGACACCTATTGGC-3' | 516 |
|
| 5'-CGTTGAGGAATCGATACTGGAAC-3' |
16S rRNA, mecA, and Panton-Valentine leukocidin genes [47].
mecA LGA251 gene [31].
arcC, aroE, glpF, gmk, pta, tpi, and yqiL genes [33].
Identification of 16S rRNA, mecA and Panton-Valentine Leukocidin (PVL) genes in S. aureus from healthy people, and MRSA isolates from clinical cases.
| Source | Samples | Positive for | Positive for MRSA | 16S rRNA |
| PVL |
|---|---|---|---|---|---|---|
|
| ---No.--- | -----No.----- | --No. (%)-- | ----------------No. (%)---------------- | ||
|
| 231 | 17 (7.4) | 17 (7.4) | 0 (0.0) | 0 (0.0) | |
|
| 319 | 25 (7.8) | 25 (7.8) | 0 (0.0) | 0 (0.0) | |
|
| 550 | 42 (7.6) | 42 (7.6) | 0 (0.0) | 0 (0.0) | |
|
| ||||||
|
| 99 | 99 (100) | 99 (100) | 99 (100) | 96 (97.0) | 11 (11.1) |
|
| 9 | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 0 (0.0) |
|
| 108 | 108 (100) | 108 (100) | 108 (100) | 105 (97.2) | 11 (10.2) |
Fig 1Dendrogram showing the genetic similarity between S. aureus isolates from humans, and of animal origin.
The scale indicates levels of similarity with a vertical line indicating the cutoff (80% level of similarity), numbers represent the sample codes, followed on the right by the sequence type (ST) and the type of the sample. *mecA-positive S. aureus in pork meat. **mecA- and mecC-negative MRSA from clinical cases.
Antimicrobial resistance profiles of Staphylococcus aureus from healthy people, and methicillin-resistance Staphylococcus aureus (MRSA) isolates from clinical cases.
| Antimicrobial resistance profile | Antimicrobial subclasses | Samples | Type | Samples |
|---|---|---|---|---|
| -----------No.---------- | --No.-- | ---------------No.--------------- | ||
|
| 5 | 5 | Clinical MRSA | 2 |
| Healthy human | 3 | |||
|
| 5 | 1 | Clinical MRSA | 1 |
|
| 5 | 5 | Clinical MRSA | 5 |
|
| 4 | 29 | Clinical MRSA | 25 |
| Clinical MRSA | 2 | |||
| Healthy human | 2 | |||
|
| 4 | 1 | Clinical MRSA | 1 |
|
| 3 | 2 | Healthy human | 2 |
|
| 3 | 3 | Clinical MRSA | 2 |
| Healthy human | 1 | |||
|
| 3 | 1 | Clinical MRSA | 1 |
|
| 3 | 1 | Clinical MRSA | 1 |
|
| 3 | 2 | Clinical MRSA | 1 |
| Healthy human | 1 | |||
|
| 3 | 55 | Clinical MRSA | 51 |
| Healthy human | 4 | |||
|
| 2 | 9 | Clinical MRSA | 36 |
| Healthy human | 6 | |||
|
| 2 | 8 | Clinical MRSA | 3 |
| Healthy human | 5 | |||
|
| 2 | 1 | Clinical MRSA | 1 |
|
| 1 | 2 | Healthy human | 2 |
|
| 1 | 22 | Clinical MRSA | 6 |
| Healthy human | 16 | |||
|
| 1 | 2 | Clinical MRSA | 2 |
Ciprofloxacin (CIP); Daptomycin (DAP); erythromycin (ERY); kanamycin (KAN); quinupristin/dalfopristin (QUI); penicillin (PEN); and tetracycline (TET).
a mecA positive.
b mecA and mecC negative.
Resistance according to CLSI (2012) criteria [34].
Minimum inhibitory concentrations (MICs) of resistant Staphylococcus aureus isolates from healthy humans and clinical cases.
| Antimicrobial Agent (breakpoints) | Resistant | MIC (μg/mL) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.5–1 | 2 | 4 | >4 | 8 | >8 | 16 | >16 | 32 | >32 | 256 | 512 | 1024 | >1024 | ||
| ----No.---- | No. | ||||||||||||||
| (%) | |||||||||||||||
|
| 7 | 107 | |||||||||||||
|
| (6.1) | (93.9) | |||||||||||||
|
| 143 | 11 | 9 | 26 | 36 | 36 | 25 | ||||||||
|
| (7.7) | (6.3) | (18.2) | (25.2) | (25.2) | (17.5) | |||||||||
|
| 8 | 2 | 2 | 4 | |||||||||||
|
| (25.0) | (25.0) | (50.0) | ||||||||||||
|
| 46 | 13 | 10 | 13 | 10 | ||||||||||
|
| (28.3) | (21.7) | (28.3) | (21.7) | |||||||||||
|
| 111 | 1 | 110 | ||||||||||||
|
| (0.9) | (99.1) | |||||||||||||
|
| 1 | 1 (100) | |||||||||||||
|
| |||||||||||||||
|
| 6 | 3 | 3 | ||||||||||||
| (50) | (50) | ||||||||||||||
Ciprofloxacin (CIP); Daptomycin (DAP); erythromycin (ERY); kanamycin (KAN); quinupristin/dalfopristin (QUI); penicillin (PEN); and tetracycline (TET).
aLevels of MIC against tested antibiotics [34].
bCriteria for Dap: susceptible ≤1 μg/mL.